T · 4594.T
BrightPath Biotherapeutics Co., Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Tokyo
- Website
- brightpathbio.com
Price · as of 2025-03-31
$52.00
Market cap 5.92B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $156.10 | +200.19% |
| Intrinsic Value(DCF) | $16.00 | -69.23% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $1,018.00 | $427.72 | $43.83 | $0.00 | $0.00 |
| 2017 | $522.00 | $247.52 | $105.87 | $0.00 | $848.69 |
| 2018 | $358.00 | $181.35 | $121.66 | $0.00 | $966.68 |
| 2019 | $238.00 | $120.07 | $69.76 | $0.00 | $2,042.48 |
| 2020 | $275.00 | $110.00 | $26.81 | $0.00 | $3,563.98 |
| 2021 | $185.00 | $74.00 | $31.20 | $0.00 | $2,395.64 |
| 2022 | $91.00 | $36.40 | $15.22 | $0.00 | $0.00 |
| 2023 | $141.00 | $56.40 | $0.00 | $0.00 | $1,364.82 |
| 2024 | $63.00 | $27.39 | $0.00 | $0.00 | $1,568.96 |
| 2025 | $40.00 | $156.10 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates BrightPath Biotherapeutics Co., Ltd.'s (4594.T) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $156.10
- Current price
- $52.00
- AI upside
- +200.19%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$16.00
-69.23% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
About BrightPath Biotherapeutics Co., Ltd.
BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.
- CEO
- Kenichi Nagai
- Employees
- 42
- Beta
- 1.64
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($16.00 ÷ $52.00) − 1 = -69.23% (DCF, example).